Overview

Study to Investigate the Natriuretic Effects, Safety, Tolerability and Pharmacokinetics of BAY94-8862

Status:
Completed
Trial end date:
2011-05-01
Target enrollment:
Participant gender:
Summary
Pharmacodynamics, pharmacokinetics, safety, and tolerability will be investigated in this single dose study. In 5 treatment groups, different dosages of BAY94-8862 will be given in healthy male subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Bayer
Treatments:
Eplerenone
Fludrocortisone
Pharmaceutical Solutions
Spironolactone